Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Conditions
Brief summary
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.
Interventions
DRUGMK0954, /Duration of Treatment : 5 Years
DRUGComparator : atenolol /Duration of Treatment : 5 Years
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 55 to 80 years * Males and females * Hypertension (160-200/95-115 mm Hg * ECG evidence of left ventricular hypertrophy
Exclusion criteria
* Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers * Myocardial infarction or stroke within 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack) | — |
Secondary
| Measure | Time frame |
|---|---|
| cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus | — |
Outcome results
None listed